[1] |
Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study[J]. Am J Pathol, 1988,132(2):265⁃277.
|
[2] |
Lansigan F, Horwitz SM, Pinter⁃Brown LC, et al. Outcomes of patients with transformed mycosis fungoides: analysis from a prospective multicenter US cohort study[J]. Clin Lymphoma Myeloma Leuk, 2020,20(11):744⁃748. doi: 10.1016/j.clml.2020. 05.001.
|
[3] |
Scarisbrick JJ, Hodak E, Bagot M, et al. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force[J]. Eur J Cancer, 2018,93:47⁃56. doi: 10.1016/j.ejca.2018.01.076.
|
[4] |
Shi HZ, Liu YX, Jiang YQ, et al. Clinical characteristics of primary cutaneous lymphoma: analysis from two centres in China[J]. Br J Dermatol, 2019,181(6):1332⁃1333. doi: 10.1111/bjd. 18266.
|
[5] |
Vural S, Akay BN, Botsalı A, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis[J]. Turk J Haematol, 2018,35(1):35⁃41. doi: 10.4274/tjh.2016. 0502.
|
[6] |
Arulogun SO, Prince HM, Ng J, et al. Long⁃term outcomes of patients with advanced⁃stage cutaneous T⁃cell lymphoma and large cell transformation[J]. Blood, 2008,112(8):3082⁃3087. doi: 10.1182/blood⁃2008⁃05⁃154609.
|
[7] |
Benner MF, Jansen PM, Vermeer MH, et al. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases[J]. Blood, 2012,119(7):1643⁃1649. doi: 10.1182/blood⁃2011⁃08⁃376319.
|
[8] |
Talpur R, Sui D, Gangar P, et al. Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides[J]. Clin Lymphoma Myeloma Leuk, 2016,16(1):49⁃56. doi: 10.1016/j.clml.2015.11.010.
|
[9] |
Booken N, Goerdt S, Klemke CD. Clinical spectrum of primary cutaneous CD30⁃positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry[J]. J Dtsch Dermatol Ges, 2012,10(5):331⁃339. doi: 10.1111/j.1610⁃0387.2011.07794.x.
|
[10] |
Fauconneau A, Pham⁃Ledard A, Cappellen D, et al. Assessment of diagnostic criteria between primary cutaneous anaplastic large⁃cell lymphoma and CD30⁃rich transformed mycosis fungoides; a study of 66 cases[J]. Br J Dermatol, 2015,172(6):1547⁃1554. doi: 10.1111/bjd.13690.
|
[11] |
Gao C, McCormack CJ, van der Weyden C, et al. The importance of differentiating between mycosis fungoides with CD30⁃positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma[J]. J Am Acad Dermatol, 2021,84(1):185⁃187. doi: 10.1016/j.jaad.2020. 04.073.
|
[12] |
陈浩, 刘排, 张磊, 等. 伴大细胞转化的蕈样肉芽肿一例[J]. 中华皮肤科杂志, 2011,44(2):88⁃90. doi: 10.3760/cma.j.issn. 0412⁃4030.2011.02.006.
|
[13] |
Hsi AC, Lee SJ, Rosman IS, et al. Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T⁃cell lymphomas: diagnostic implications[J]. J Am Acad Dermatol, 2015,72(1):159⁃167. doi: 10.1016/j.jaad.2014. 09.022.
|
[14] |
Nicolae⁃Cristea AR, Benner MF, Zoutman WH, et al. Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30⁃positive lymphoproliferative disease[J]. Br J Dermatol, 2015,172(3):784⁃788. doi: 10.1111/bjd.13476.
|
[15] |
Guitart J, Martinez⁃Escala ME, Deonizio JM, et al. CD30(+) cutaneous lymphoproliferative disorders with pseudocarcino⁃matous hyperplasia are associated with a T⁃helper⁃17 cytokine profile and infiltrating granulocytes[J]. J Am Acad Dermatol, 2015,72(3):508⁃515. doi: 10.1016/j.jaad.2014.11.021.
|
[16] |
Mitteldorf C, Robson A, Tronnier M, et al. Galectin⁃3 expression in primary cutaneous CD30⁃positive lymphoproliferative disorders and transformed mycosis fungoides[J]. Dermatology, 2015,231(2):164⁃170. doi: 10.1159/000431313.
|
[17] |
Gao Y, Liu F, Sun J, et al. Differential SATB1 expression reveals heterogeneity of cutaneous T⁃cell lymphoma[J]. J Invest Dermatol, 2021,141(3):607⁃618.e6. doi: 10.1016/j.jid.2020.05. 120.
|
[18] |
Pham⁃Ledard A, Prochazkova⁃Carlotti M, Laharanne E, et al. IRF4 gene rearrangements define a subgroup of CD30⁃positive cutaneous T⁃cell lymphoma: a study of 54 cases[J]. J Invest Dermatol, 2010,130(3):816⁃825. doi: 10.1038/jid.2009.314.
|
[19] |
Vonderheid EC, Jakubowski J, Hou JS. High⁃scatter lymphocytes in the blood of erythrodermic cutaneous T⁃cell lymphoma: evidence for large⁃cell transformation?[J]. Clin Lymphoma Myeloma Leuk, 2020,20(9):624⁃631.e2. doi: 10. 1016/j.clml.2020.04.017.
|
[20] |
Alberti⁃Violetti S, Talpur R, Schlichte M, et al. Advanced⁃stage mycosis fungoides and Sézary syndrome: survival and response to treatment[J]. Clin Lymphoma Myeloma Leuk, 2015,15(6):e105⁃e112. doi: 10.1016/j.clml.2015.02.027.
|
[21] |
Richardson NC, Kasamon YL, Chen H, et al. FDA approval summary: brentuximab vedotin in first⁃line treatment of peripheral T⁃Cell lymphoma[J]. Oncologist, 2019,24(5):e180⁃e187. doi: 10.1634/theoncologist.2019⁃0098.
|